Clinical Trials Logo
  1. Home
  2. Other
  3. NCT03692442

Evaluation of Efficacy and Toxicity of Nivolumab Monotherapy for Advanced Non-small Cell Lung Cancer After First-line Treatment Failure Based on Second-generation Sequencing and Liquid Chip Platform

Lung Cancer Non-small Cell Stage IV Clinical Trial

Official title:
Evaluation of Efficacy and Toxicity of Nivolumab Monotherapy for Advanced Non-small Cell Lung Cancer After First-line Treatment Failure Based on Second-generation Sequencing and Liquid Chip Platform

Clinical Trial Summary

In order to understand the efficacy and side effects of lung cancer immunotherapy, at least 30 patients with lung cancer who were treated with immunotherapy were enrolled. The second-generation sequencing technology and liquid phase factor platform were used for detection, and clinical imaging and other evaluation methods were used to explore the immunotherapy efficacy and side effects affecting lung cancer。

Clinical Trial Description

In order to understand the efficacy and side effects of lung cancer immunotherapy, at least 30 patients with lung cancer who were treated with immunotherapy were enrolled. The second-generation sequencing technology and liquid phase factor platform were used for detection, and clinical imaging and other evaluation methods were used to explore the immunotherapy efficacy and side effects affecting lung cancer。 ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03692442
Study type Observational
Source Guangzhou Institute of Respiratory Disease
Contact
Status Recruiting
Phase
Start date May 1, 2018
Completion date March 31, 2019
View Details
See also
  Status Clinical Trial Phase
Terminated NCT03866980 - A Study of Anti-PD-1 AK105 in Patients With Metastatic Nonsquamous Non-small Cell Lung Cancer Phase 3
Recruiting NCT03769103 - Study of Osimertinib + SRS vs Osimertinib Alone for Brain Metastases in EGFR Positive Patients With NSCLC Phase 2
Not yet recruiting NCT06463171 - Phase II Trial of Almonertinib Plus Lastet for EGFR+ Non-small Cell Lung Cancer Phase 2
Terminated NCT02129699 - Survival imProvement in Lung cancEr iNduced by DenOsUmab theRapy Phase 3
Recruiting NCT05127382 - Osimertinib as 1st Line Therapy for Patients With Advanced EGFR Positive Non-Small Cell Lung Cancer
Completed NCT03866993 - A Study of Anti-PD-1 AK105 in Patients With Metastatic Squamous Non-small Cell Lung Cancer Phase 3
Not yet recruiting NCT04184921 - Combination of Osimertinib and Aspirin to Treat EGFR Mutation NSCLC Patients